Vol. 21/No. 12

During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

The rapidly developing nature of our knowledge about the coronavirus disease 2019 and the need to respond quickly to the pandemic are prompting community oncologists to search for ways to maintain their practices while improving the quality of care for their patients.

Investigators are using a novel clinical trial design to test multiple treatment strategies in an effort to define the standard of care in squamous cell carcinoma of the penis.

Nearly 5 years after its approval for patients with multiple myeloma, daratumumab is now available in a formulation that can be administered in a fraction of the time required with the original agent.

Institutions are slowly but steadily resuming their investigational efforts, examining both the temporary and lasting effects the pandemic has left on their centers.

Bhavana Pothuri, MD, discusses the practice-changing implications of niraparib’s approval in ovarian cancer.

A panel of experts provide their insights on how and when they are using novel imaging versus conventional imaging. They also discuss the data regarding the FDA-approved AR-targeted therapies, how they select between them, and their strategies for mitigating any adverse events.

Oncology practices large and small are starting to tap into the power of data analytics and artificial intelligence to help identify patients at risk of relapse or adverse effects and to assist in making clinical decisions on care.

The explosion of COVID-19 studies illustrates questions that have plagued oncology research.